Structure Therapeutics (NASDAQ:GPCR) Shares Gap Down to $44.66

Structure Therapeutics Inc. (NASDAQ:GPCR) gapped down prior to trading on Wednesday . The stock had previously closed at $44.66, but opened at $40.00. Structure Therapeutics shares last traded at $38.95, with a volume of 1,231,945 shares traded.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Structure Therapeutics in a report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price target for the company. BMO Capital Markets lifted their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, July 1st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Friday, May 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $85.25.

Structure Therapeutics Trading Down 11.7 %

The business’s fifty day moving average price is $42.07 and its 200 day moving average price is $41.58. The company has a market capitalization of $1.84 billion, a P/E ratio of -48.64 and a beta of -3.58.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.02. Equities research analysts anticipate that Structure Therapeutics Inc. will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock valued at $178,216,000 after purchasing an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the period. Federated Hermes Inc. grew its stake in Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock valued at $92,411,000 after buying an additional 1,157,006 shares during the last quarter. RA Capital Management L.P. raised its holdings in Structure Therapeutics by 210.2% in the 1st quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares during the period. Finally, Capital International Investors acquired a new stake in Structure Therapeutics during the fourth quarter worth approximately $34,647,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.